HS-1793
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 408136

CAS#: 927885-00-5

Description: HS-1793 is a resveratrol analogue. HS-1793 downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. HS-1793, enhances the effects of radiation therapy through the induction of anti-tumor immunity in mammary tumor growth. HS-1793 enhances radiosensitivity of mouse-derived breast cancer cells under hypoxic conditions.

Chemical Structure

img
HS-1793
CAS# 927885-00-5
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 408136
Name: HS-1793
CAS#: 927885-00-5
Chemical Formula: C16H12O3
Exact Mass: 252.08
Molecular Weight: 252.269
Elemental Analysis: C, 76.18; H, 4.79; O, 19.03

Price and Availability

Size Price Availability Quantity
25mg USD 250 2 Weeks
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 2150 2 Weeks
1g USD 3250 2 Weeks
2g USD 5850 2 Weeks
Bulk inquiry

Synonym: HS-1793; HS 1793; HS1793;

IUPAC/Chemical Name: 4-(6-Hydroxy-2-naphthalenyl)1,3-benzenediol

InChi Key: BXZJBSHLEZAMOP-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H12O3/c17-13-4-3-10-7-12(2-1-11(10)8-13)15-6-5-14(18)9-16(15)19/h1-9,17-19H

SMILES Code: OC1=CC=C(C2=CC=C3C=C(O)C=CC3=C2)C(O)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: HS-1793 is a Resveratrol (HY-16561) analogue with antitumor activities in a variety of cancer cell lines. HS-1793 induces cell apoptosis.
In vitro activity: Results showed that HS-1793 significantly inhibited cell viability in A549 and H460 cells (high dose; 7.5 and 10 µM) but not in H1299 cells, suggesting that A549 and H460 cells were HS-1793 sensitive (Fig. S1). Reference: Oncol Lett. 2022 Jul 1;24(2):290. https://pubmed.ncbi.nlm.nih.gov/35928802/
In vivo activity: To evaluate the anticancer effects of HS-1793 in vivo, triple-negative MDA-MB-231 breast cancer xenografts were established in nude mice. HS-1793 significantly suppressed the growth of breast cancer tumor xenografts, without any apparent toxicity. Reference: Int J Oncol. 2017 Aug;51(2):715-723. https://pubmed.ncbi.nlm.nih.gov/28656256/

Preparing Stock Solutions

The following data is based on the product molecular weight 252.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Lim C, Lee PCW, Shim S, Jang SW. HS-1793 inhibits cell proliferation in lung cancer by interfering with the interaction between p53 and MDM2. Oncol Lett. 2022 Jul 1;24(2):290. doi: 10.3892/ol.2022.13410. PMID: 35928802; PMCID: PMC9344265. 2. Kim DH, Kim MJ, Sung B, Suh H, Jung JH, Chung HY, Kim ND. Resveratrol analogue, HS-1793, induces apoptotic cell death and cell cycle arrest through downregulation of AKT in human colon cancer cells. Oncol Rep. 2017 Jan;37(1):281-288. doi: 10.3892/or.2016.5219. Epub 2016 Nov 7. PMID: 27840966. 3. Kim DH, Sung B, Kim JA, Kang YJ, Hwang SY, Hwang NL, Suh H, Choi YH, Im E, Chung HY, Kim ND. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. Int J Oncol. 2017 Aug;51(2):715-723. doi: 10.3892/ijo.2017.4058. Epub 2017 Jun 27. PMID: 28656256.
In vitro protocol: 1. Lim C, Lee PCW, Shim S, Jang SW. HS-1793 inhibits cell proliferation in lung cancer by interfering with the interaction between p53 and MDM2. Oncol Lett. 2022 Jul 1;24(2):290. doi: 10.3892/ol.2022.13410. PMID: 35928802; PMCID: PMC9344265. 2. Kim DH, Kim MJ, Sung B, Suh H, Jung JH, Chung HY, Kim ND. Resveratrol analogue, HS-1793, induces apoptotic cell death and cell cycle arrest through downregulation of AKT in human colon cancer cells. Oncol Rep. 2017 Jan;37(1):281-288. doi: 10.3892/or.2016.5219. Epub 2016 Nov 7. PMID: 27840966.
In vivo protocol: 1. Kim DH, Sung B, Kim JA, Kang YJ, Hwang SY, Hwang NL, Suh H, Choi YH, Im E, Chung HY, Kim ND. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. Int J Oncol. 2017 Aug;51(2):715-723. doi: 10.3892/ijo.2017.4058. Epub 2017 Jun 27. PMID: 28656256.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kim JS, Jeong SK, Oh SJ, Lee CG, Kang YR, Jo WS, Jeong MH. The resveratrol analogue, HS‑1793, enhances the effects of radiation therapy through the induction of anti‑tumor immunity in mammary tumor growth. Int J Oncol. 2020 Jun;56(6):1405-1416. doi: 10.3892/ijo.2020.5017. Epub 2020 Mar 19. PMID: 32236622; PMCID: PMC7170036.


2: Song IS, Jeong YJ, Jeong SH, Kim HK, Ha NC, Shin M, Ko KS, Rhee BD, Shim S, Jang SW, Han J. Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma. Cancer Lett. 2018 Sep 28;432:205-215. doi: 10.1016/j.canlet.2018.06.020. Epub 2018 Jun 19. PMID: 29933047.


3: Kim DH, Sung B, Kim JA, Kang YJ, Hwang SY, Hwang NL, Suh H, Choi YH, Im E, Chung HY, Kim ND. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. Int J Oncol. 2017 Aug;51(2):715-723. doi: 10.3892/ijo.2017.4058. Epub 2017 Jun 27. PMID: 28656256.


4: Kim DH, Kim MJ, Sung B, Suh H, Jung JH, Chung HY, Kim ND. Resveratrol analogue, HS-1793, induces apoptotic cell death and cell cycle arrest through downregulation of AKT in human colon cancer cells. Oncol Rep. 2017 Jan;37(1):281-288. doi: 10.3892/or.2016.5219. Epub 2016 Nov 7. PMID: 27840966.


5: Choi YJ, Heo K, Park HS, Yang KM, Jeong MH. The resveratrol analog HS-1793 enhances radiosensitivity of mouse-derived breast cancer cells under hypoxic conditions. Int J Oncol. 2016 Oct;49(4):1479-88. doi: 10.3892/ijo.2016.3647. Epub 2016 Aug 3. PMID: 27498957.


6: Jeong MH, Yang K, Lee CG, Jeong DH, Park YS, Choi YJ, Kim JS, Oh SJ, Jeong SK, Jo WS. In Vitro Genotoxicity Assessment of a Novel Resveratrol Analogue, HS-1793. Toxicol Res. 2014 Sep;30(3):211-20. doi: 10.5487/TR.2014.30.3.211. PMID: 25343016; PMCID: PMC4206749.


7: Jeong SK, Yang K, Park YS, Choi YJ, Oh SJ, Lee CW, Lee KY, Jeong MH, Jo WS. Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor associated macrophages. Int Immunopharmacol. 2014 Oct;22(2):303-10. doi: 10.1016/j.intimp.2014.07.004. Epub 2014 Jul 18. PMID: 25042796.


8: Jeong MH, Yang KM, Jeong DH, Lee CG, Oh SJ, Jeong SK, Lee KW, Jo YR, Jo WS. Protective activity of a novel resveratrol analogue, HS-1793, against DNA damage in 137Cs-irradiated CHO-K1 cells. J Radiat Res. 2014 May;55(3):464-75. doi: 10.1093/jrr/rrt140. Epub 2014 Jan 7. PMID: 24403520; PMCID: PMC4014163.


9: Kim JA, Kim DH, Hossain MA, Kim MY, Sung B, Yoon JH, Suh H, Jeong TC, Chung HY, Kim ND. HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells. Int J Oncol. 2014 Feb;44(2):473-80. doi: 10.3892/ijo.2013.2207. Epub 2013 Dec 5. PMID: 24316714.


10: Kim DH, Hossain MA, Kim MY, Kim JA, Yoon JH, Suh HS, Kim GY, Choi YH, Chung HY, Kim ND. A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and VEGF expression, and migration in human prostate cancer cells. Int J Oncol. 2013 Dec;43(6):1915-24. doi: 10.3892/ijo.2013.2116. Epub 2013 Oct 2. PMID: 24100602.


11: Jeong SH, Hanh TM, Kim HK, Lee SR, Song IS, Noh SJ, Song S, Suh H, Kim N, Rhee BD, Ko KS, Han J. HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4225-9. doi: 10.1016/j.bmcl.2013.05.010. Epub 2013 May 15. PMID: 23735745.


12: Jeong SH, Song IS, Kim HK, Lee SR, Song S, Suh H, Yoon YG, Yoo YH, Kim N, Rhee BD, Ko KS, Han J. An analogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 cells via inhibition of mitochondrial biogenesis gene expression. Mol Cells. 2012 Oct;34(4):357-65. doi: 10.1007/s10059-012-0081-7. Epub 2012 Oct 18. PMID: 23104437; PMCID: PMC3887771.


13: Choi YJ, Yang KM, Kim SD, Yoo YH, Lee SW, Seo SY, Suh H, Yee ST, Jeong MH, Jo WS. Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells. Exp Ther Med. 2012 Apr;3(4):592-598. doi: 10.3892/etm.2012.472. Epub 2012 Feb 3. PMID: 22969934; PMCID: PMC3438654.


14: Kim HJ, Yang KM, Park YS, Choi YJ, Yun JH, Son CH, Suh HS, Jeong MH, Jo WS. The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells. Int J Oncol. 2012 Nov;41(5):1628-34. doi: 10.3892/ijo.2012.1615. Epub 2012 Aug 31. PMID: 22940714; PMCID: PMC3583985.


15: Jeong MH, Yang KM, Choi YJ, Kim SD, Yoo YH, Seo SY, Lee SH, Ryu SR, Lee CM, Suh Hs, Jo WS. Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4+CD25+ regulatory T cells in FM3A tumor bearing mice. Int Immunopharmacol. 2012 Nov;14(3):328-33. doi: 10.1016/j.intimp.2012.07.018. Epub 2012 Aug 9. PMID: 22884509.


16: Jeong NY, Yoon YG, Rho JH, Lee JS, Lee SY, Yoo KS, Song S, Suh H, Choi YH, Yoo YH. The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int J Oncol. 2011 Jun;38(6):1597-604. doi: 10.3892/ijo.2011.979. Epub 2011 Mar 17. PMID: 21424121.


17: Um HJ, Bae JH, Park JW, Suh H, Jeong NY, Yoo YH, Kwon TK. Differential effects of resveratrol and novel resveratrol derivative, HS-1793, on endoplasmic reticulum stress-mediated apoptosis and Akt inactivation. Int J Oncol. 2010 Apr;36(4):1007-13. doi: 10.3892/ijo_00000581. PMID: 20198347.


18: Jeong SH, Lee JS, Jeong NY, Kim TH, Yoo KS, Song S, Suh H, Kwon TK, Park BS, Yoo YH. A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol. 2009 Dec;35(6):1353-60. doi: 10.3892/ijo_00000453. PMID: 19885558.


19: Jeong SH, Jo WS, Song S, Suh H, Seol SY, Leem SH, Kwon TK, Yoo YH. A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem Pharmacol. 2009 Apr 15;77(8):1337-47. doi: 10.1016/j.bcp.2009.01.002. Epub 2009 Jan 20. PMID: 19426672.


20: Ha YM, Chung SW, Song S, Lee H, Suh H, Chung HY. 4-(6-Hydroxy-2-naphthyl)-1,3-bezendiol: a potent, new tyrosinase inhibitor. Biol Pharm Bull. 2007 Sep;30(9):1711-5. doi: 10.1248/bpb.30.1711. PMID: 17827726.